Today: 20 March 2026
Subscribe
Browse Category

LSE:BAB.L 10 December 2025 - 3 February 2026

Babcock share price rises 2% as buyback filings roll on — what matters for BAB.L next

Babcock share price rises 2% as buyback filings roll on — what matters for BAB.L next

Babcock International shares rose 2.3% to 1,456 pence by 0923 GMT Tuesday, valuing the company at about £7.25 billion. The company disclosed recent buybacks, including 18 shares at £14.20–£14.27 each on Feb. 2 and 6,927 shares at 1,426–1,462 pence on Jan. 30, leaving 6.14 million shares in treasury. Issued share capital stands at 505.6 million, with 499.5 million voting rights as of Jan. 31.
3 February 2026
··
Babcock share price today: BAB.L slips despite fresh buybacks and higher broker targets

Babcock share price today: BAB.L slips despite fresh buybacks and higher broker targets

Babcock shares slipped 0.34% to 1,449p in early London trading after announcing further share buybacks. Jefferies and JPMorgan raised their target prices to 1,670p and 1,700p, respectively, as investors watch for a June board handover. The company reaffirmed its FY26 outlook and margin target, citing contracted revenue and new Arrowhead licence deals in Indonesia.
27 January 2026
··
AUKUS Boost for Scotland: Rosyth Dockyard to Build US Virginia-Class Submarine Modules as HMS Formidable Keel Is Laid

AUKUS Boost for Scotland: Rosyth Dockyard to Build US Virginia-Class Submarine Modules as HMS Formidable Keel Is Laid

Babcock International will build complex assemblies for US Virginia-class nuclear submarines at Scotland’s Rosyth dockyard under a new contract with Huntington Ingalls Industries. The deal, announced December 10, marks the first time such work for Newport News Shipbuilding is outsourced to the UK. Rosyth laid the keel for the Royal Navy’s HMS Formidable a day earlier. The agreement is expected to boost jobs and capacity at the Scottish yard.
10 December 2025
··

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Go toTop